Toxicity and clinical response after CTL therapy
Patient no. . | Toxicity . | Clinical response . | Outcome . |
|---|---|---|---|
| Treated in remission | |||
| 729 | None | N/A | Remains in remission > 27 mo |
| 606 | None | N/A | Remains in remission > 26 mo |
| 697 | None | N/A | Remains in remission > 25 mo |
| 815 | None | N/A | Remains in remission > 19 mo |
| Treated with relapsed or refractory disease | |||
| 845 | Swelling at tumor site | No response then PR after chemotherapy | PR for 4 months then progressed and died at 12 mo |
| 894 | None | CR | Remains in remission > 23 mo after CTLs |
| 389 | None | CR | Remains in remission > 11 mo after CTLs |
| 918 | None | PR | PR for 12 mo after CTLs then relapsed |
| 1042 | None | Stable disease | Stable disease for > 14 mo |
| 1046 | None | No response | Died of disease at 3 mo |
Patient no. . | Toxicity . | Clinical response . | Outcome . |
|---|---|---|---|
| Treated in remission | |||
| 729 | None | N/A | Remains in remission > 27 mo |
| 606 | None | N/A | Remains in remission > 26 mo |
| 697 | None | N/A | Remains in remission > 25 mo |
| 815 | None | N/A | Remains in remission > 19 mo |
| Treated with relapsed or refractory disease | |||
| 845 | Swelling at tumor site | No response then PR after chemotherapy | PR for 4 months then progressed and died at 12 mo |
| 894 | None | CR | Remains in remission > 23 mo after CTLs |
| 389 | None | CR | Remains in remission > 11 mo after CTLs |
| 918 | None | PR | PR for 12 mo after CTLs then relapsed |
| 1042 | None | Stable disease | Stable disease for > 14 mo |
| 1046 | None | No response | Died of disease at 3 mo |
N/A indicates not applicable; CR, complete remission; and PR, partial response according to the international criteria proposed by the Response Evaluation Criteria in Solid Tumors Committee.29